MOHAMMED KHALIL, AKRAM AL SALEH, HANA MAKHAMREH, RABAB TAYEM, MOHAMMAD ABUFARAH, ABDULLAH ZUBI, OMAİMAH NAJIB, MOHAMMAD BADER, NAJİ NAJIB, SULİMAN ALFAYOUMI, NASİR IDKAIDEK
Journal of Research in Pharmacy - 2022;26(5):1411-1419
Ticagrelor is an orally administered antiplatelet agent that has been approved for the reduction of cardiovascular risk in patients with history of cardiovascular disease. However, Ticagrelor can also cause adverse effects, including dyspnea. Ticagrelor plasma and saliva concentrations of 63 Jordanian patients were measured using a sensitive LCMS/MS method. Ticagrelor was not excreted in saliva as it corresponds to the Class IV salivary excretion classification system. The correlation between plasma ticagrelor concentrations and the occurrence of dyspnea was examined to establish a therapeutic window for plasma ticagrelor. A physiologically-based pharmacokinetic (PBPK) model of ticagrelor was built and validated using previously- published plasma data. The validated model was then used to predict the factors affecting ticagrelor plasma concentrations. A loading dose of 135 mg (1.5 tablet) instead of 2 tablets has been suggested to maintain its therapeutic effect and avoid dyspnea.
